pI: 7.3864 |
Length (AA): 204 |
MW (Da): 24558 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
97 | 197 | 3gwl (A) | 99 | 197 | 14.00 | 0 | 0.37 | 0.763098 | -1.45 |
104 | 203 | 3mbg (A) | 105 | 199 | 33.00 | 0.72 | 0.89 | 0.811996 | -0.68 |
104 | 198 | 1jr8 (A) | 16 | 108 | 17.00 | 0 | 0.34 | 0.753686 | -1.4 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Ookinete. | Otto TD |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | 4 hs Ring, 16 hs Trophozoite. | Otto TD |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Gametocyte, 22 hs Schizont, Erthyrocytic stages, Male gametocyte. | Otto TD Yeoh LM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Female gametocyte. | Yeoh LM |
Otto TD | A comprehensive evaluation of rodent malaria parasite genomes and gene expression. |
Yeoh LM | Comparative transcriptomics of female and male gametocytes in Plasmodium berghei and the evolution of sex in alveolates. |
Ortholog group members (OG5_147399)
Species | Accession | Gene Product |
---|---|---|
Babesia bovis | BBOV_I002010 | conserved hypothetical protein |
Cryptosporidium hominis | Chro.80170 | hypothetical protein |
Neospora caninum | NCLIV_032750 | erv1 / Alr family domain-containing protein, putative |
Plasmodium berghei | PBANKA_1200900 | conserved Plasmodium protein, unknown function |
Plasmodium falciparum | PF3D7_1002500 | conserved Plasmodium protein, unknown function |
Plasmodium knowlesi | PKNH_0801300 | conserved Plasmodium protein, unknown function |
Plasmodium vivax | PVX_094325 | hypothetical protein, conserved |
Toxoplasma gondii | TGME49_232815 | Erv1 / Alr family protein |
Theileria parva | TP03_0130 | hypothetical protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
PBANKA_1200900 this record | Plasmodium berghei | Essential | plasmo |
TGME49_232815 | Toxoplasma gondii | Probably essential | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.